BCPC

Balchem is a high-quality specialty-ingredients company (nutrition, animal health, food and pharma) with the consistent, defensive growth profile investors prize. FY2025 was strong: revenue grew 8.8% to $1.04B, gross margin expanded to 35.7%, operating income rose 14.4% to $209M (a healthy 20.2% operating margin), and net income jumped 20.5% to $155M with diluted EPS up 20.9% to $4.75. The multi-year record is steady and improving — net income has risen from $96.1M (FY2021) — and the operating leverage (earnings growing roughly 2.5x faster than revenue) reflects a richer product mix and pricing power in differentiated ingredients.

The balance sheet is pristine: liabilities/equity of just 0.34x, $1.26B of equity (+9.3%), $1.12B of retained earnings, and minimal debt. The business is cash-generative — operating cash flow grew 19.0% to $217M — and management has begun returning more capital, with buybacks surging to $108M and a dividend raised 10.6% to $28.3M. This is exactly the kind of low-leverage, high-return, defensively-positioned compounder that holds up well across cycles.